Metabolic Manipulation in Chronic Heart Failure

Status Completed

Clinical Trial Summary

Conventional measures used for the treatment of chronic heart failure act predominantly by reducing the work performed by the heart. In a recent study, the investigators showed that one drug (perhexiline) substantially improved symptoms and cardiac function in heart failure. The investigators wish to confirm these findings and test whether or not this drug acts by altering the heart's energy source thus augmenting the energetic status and work efficiency of the heart.

Clinical Trial Description

Perhexiline maleate is an antianginal agent which increases the efficiency of energy production by shifting substrate utilisation from free fatty acids towards glucose. We showed that perhexiline therapy was highly effective in improving exercise capacity, symptoms and cardiac function in patients with systolic heart failure of both ischaemic and non ischaemic aetiology. Perhexiline acts by inhibiting both carnitine palmitoyl transferase-1 (CPT-1) and CPT-2, which are key enzymes in mitochondrial free fatty acid uptake. This leads to increased myocardial glucose substrate utilization. Further we wish to ascertain whether or not this drug improves cardiac energetics and efficiency by altering substrate utilization. In this proposal we will assess the cardiac function (by cardiac Magnetic Resonance Imaging MRI), cardiac energetic status (by cardiac Magnetic Resonance Spectroscopy MRS), cardiac efficiency (via pressure-volume loops) and substrate utilization (via left and right heart catheterization), following one month of perhexiline therapy or placebo in patients with symptomatic idiopathic dilated cardiomyopathy on optimal conventional heart failure medications. An interim analysis is planned after 20 patients. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00841139
Study type	Interventional
Source	University Hospital Birmingham NHS Foundation Trust
Contact
Status	Completed
Phase	Phase 2
Start date	February 2009
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03597646` - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure	N/A
Terminated	`NCT04065997` - Apogee International
Withdrawn	`NCT03675113` - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure	N/A
Completed	`NCT02916160` - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study	Phase 4
Completed	`NCT03126656` - Effects of Testosterone on Myocardial Repolarization	Phase 4
Completed	`NCT02247245` - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.	N/A
Completed	`NCT02268500` - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)	Phase 4
Terminated	`NCT01906957` - Cognition and Exercise Training	N/A
Completed	`NCT01919918` - Muscle Afferent Feedback Effects in Patients With Heart Failure	Phase 1
Not yet recruiting	`NCT01669395` - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial	N/A
Completed	`NCT00984529` - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia	N/A
Recruiting	`NCT00863421` - Sleep Disordered Breathing in Patients With Chronic Heart Failure	N/A
Completed	`NCT02840565` - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453	Phase 1
Completed	`NCT02441218` - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study	Phase 3
Completed	`NCT00149409` - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure	Phase 2/Phase 3
Terminated	`NCT05532046` - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)	Phase 1
Recruiting	`NCT04984928` - Readmission Risk of Patients With Heart Failure.
Completed	`NCT02814097` - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction	Phase 2
Active, not recruiting	`NCT05560737` - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting	`NCT03286127` - Palliative Outcome Evaluation Muenster I